# Leiphone interviews Leimang Bio on low-dose CAR-T at 1‰ of standard dose

> Original title: 莱芒生物：用1‰剂量，重写CAR-T的成本和疗效公式

- Source: Leiphone
- Published: 2026-11-02T06:15:00.000Z
- Bad Influence: https://badinfluence.news/items/w06y6j6ehxsfr7ysucgcpemmt
- Original: https://www.leiphone.com/category/aihealth/Ls0rEvCHmgKUScmR.html

## Summary

Leiphone AI Tech Review interviews Leimang Bio vice president Tong Duyue about its metabolism-enhanced CAR-T therapy, which uses 1‰ of the standard dose. The company reports 100% complete response in dozens of relapsed or refractory hematologic cancer and lupus patients, and says it has cut manufacturing cost to under 100,000 yuan, with a goal below 50,000 yuan. Leimang has received two FDA IND approvals and three CDE IND clearances, and plans to begin clinical Phase I for hematologic and autoimmune indications.

## Why it matters

The interview gives concrete dose, cost, and regulatory figures behind a counterintuitive CAR-T mechanism, useful for judging whether low-dose cell therapy can scale.